HER-2 exon 20 mutation
|
NSCLC
|
HER-2 exon 20 mutation
|
NSCLC
|
HM 78136B Sensitive: B - Late Trials
|
HM 78136B Sensitive: B - Late Trials
|
HER-2 exon 20 mutation
|
NSCLC
|
HER-2 exon 20 mutation
|
NSCLC
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
HER-2 exon 20 mutation
|
NSCLC
|
HER-2 exon 20 mutation
|
NSCLC
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
HER-2 exon 20 mutation
|
NSCLC
|
HER-2 exon 20 mutation
|
NSCLC
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|